SOURCE: Barrier Therapeutics, Inc.

February 22, 2007 12:00 ET

Barrier Therapeutics to Release Fourth Quarter and Full Year 2006 Financial Results on February 28, 2007

Company to Host Conference Call on February 28, 2007 at 5:00 p.m. ET

PRINCETON, NJ -- (MARKET WIRE) -- February 22, 2007 -- Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company developing and commercializing products in the field of dermatology, is scheduled to release financial results for the fourth quarter and full year of 2006 on Wednesday, February 28, 2007 at approximately 4:00 p.m. ET. The company will host a conference call on February 28 at 5:00 p.m. ET to provide a company update and discuss the financial results for the quarter. Interested investors can listen to the call live over the Internet on the investor relations section of the company's web site located at or by dialing 1-800-573-4842 (U.S.) or 1-617-224-4327 (International) and using conference ID code: 37699152.

What:    Barrier Therapeutics, Inc. Fourth Quarter and Full Year
         2006 Corporate Update and Financial Results Conference

When:    Wednesday, February 28, 2007 at 5:00 p.m. ET

Where:   The investor relations section of the Company's web site
         located at

How:     Live over the Internet -- Simply log on to the web at
         the address above, or dial 1-800-573-4842 (U.S.) or
         1-617-224-4327 (International) and use conference
         ID code: 37699152

About Barrier Therapeutics

Barrier Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of products in the field of dermatology. Barrier Therapeutics currently markets three pharmaceutical products in the United States: Xolegel™ (ketoconazole, USP) Gel, 2%, for seborrheic dermatitis; Vusion™ (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment, for diaper dermatitis complicated by documented candidiasis; and Solagé® (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. Barrier Therapeutics has other product candidates in various stages of clinical development for the treatment of a range of dermatological conditions, including acne, psoriasis, onychomycosis and other fungal infections such as tinea versicolor. The company is headquartered in Princeton, New Jersey and has wholly owned subsidiaries in Geel, Belgium and Ontario, Canada. More information about Barrier Therapeutics can be found on its corporate website at:

Xolegel, Vusion and Solagé are trademarks of Barrier Therapeutics, Inc.

Contact Information

  • Contact:
    Barrier Therapeutics, Inc.
    Anne M. VanLent
    (609) 945-1202